Abpro Holdings, Inc.
Abpro Holdings, Inc. is a U.S.-based biotechnology company formed through a reverse recapitalization in November 2024, when Atlantic Coastal Acquisition Corp. II combined with Legacy Abpro and began trading on Nasdaq. The company is focused on developing biologic product candidates and has generated only limited research and development services revenue to date, including work performed for Celltrion related to ABP-102 development. Its business model is still pre-commercial, so value creation depends on advancing product candidates through preclinical and clinical development, securing regulatory approvals, and eventually monetizing assets through product sales or collaborations. The company also uses partnerships, licensing, and external financing to fund operations while it remains in a development stage.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueTherapeutic biologic programs being advanced through preclinical and clinical development.
Fee-based R&D work performed for partners, including development support tied to specific programs such as ABP-102.
Partnering structures that may provide upfront, milestone, or other payments while sharing development or commercialization rights.
Externalized activities needed to advance product candidates, including outsourced manufacturing and related technical work.
Products
Reported · share of revenue- Collaboration Revenue81.1 %
- Royalty18.9 %
Source: 10-K FY2023, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Abpro’s current paying customer base appears narrow and partner-driven rather than broad commercial end-market demand. The company has disclosed research and development services revenue from Celltrion, indicating that biopharma partners can be direct customers for development work. More broadly, future customers would likely include pharmaceutical or biotechnology collaborators that license programs, fund development, or co-develop assets. If the company successfully commercializes a product candidate, the end customer base would shift to healthcare providers, hospitals, and patients, but that stage has not yet been reached.
Companies such as Celltrion that may pay for development services, co-development, or access to product candidates.
Partners that provide non-dilutive funding or milestone payments in exchange for development or commercialization rights.
Hospitals, physicians, and patients that would buy or use an approved biologic product if commercialization succeeds.
Strategy
Abpro’s near-term strategy is centered on preserving liquidity, advancing product candidates, and finding external funding sources to support development. Management explicitly expects to rely on equity, debt, collaboration agreements, strategic alliances, and research grants until substantial product revenue exists. The company also appears focused on moving preclinical and clinical programs forward while managing the higher general and administrative burden of operating as a public company. In practice, this means the strategic priority is not scale today, but keeping programs alive long enough to reach value-inflection milestones such as clinical data, partnerships, or regulatory progress.
The company states its cash is not sufficient to fund operations for 12 months, so financing is essential to continue development.
Clinical and preclinical progress is the main path to future product revenue and partner interest.
Collaborations can provide funding and reduce reliance on dilutive capital raises while preserving development optionality.
Geography
Abpro Holdings is headquartered in the United States and now trades on Nasdaq, so its corporate, financing, and reporting footprint is U.S.-centric. The available excerpts do not disclose a country-level revenue split, and the company’s current revenue base is too limited to support a meaningful geographic map. Operationally, a development-stage biotech like Abpro typically relies on U.S. public markets, U.S. regulatory pathways, and outsourced global manufacturing or research partners. Geographic exposure therefore matters less through current sales concentration and more through access to capital, clinical execution, and partner relationships across markets.
Risks
The most immediate risk is liquidity and going-concern uncertainty, because management has disclosed that available cash is not sufficient to fund operations for at least 12 months. The company also faces substantial execution risk in drug development, where preclinical and clinical programs can fail, be delayed, or require more capital than expected. Nasdaq listing compliance is another material company-specific risk, since failure to meet bid price and market value requirements could lead to delisting and reduced trading liquidity. More broadly, biotech companies face regulatory risk, partner concentration risk, manufacturing scale-up risk, and the possibility that market conditions make capital raising more expensive or unavailable.
- Insufficient cash to fund operationsImpact: CriticalLikelihood: High
Management disclosed that cash is not sufficient to operate for at least 12 months, creating substantial doubt about going concern.
Exposure: Company-wide operations and development programs
- Nasdaq delistingImpact: HighLikelihood: High
The company received notices regarding minimum bid price and other listing requirements, and failure to regain compliance could reduce liquidity and market access.
Exposure: Public equity trading and capital raising
- Clinical development failureImpact: High
The business depends on advancing biologic candidates through preclinical and clinical stages, where failure would eliminate future product revenue potential.
Exposure: Product pipeline
- Dilution from external financingImpact: MediumLikelihood: High
The company expects to fund itself through equity and convertible debt, which can materially dilute existing shareholders.
Exposure: Capital structure
Accounting
Judgemental itemsRevenue is tied to development services rather than product sales, so timing and contract scope determine when revenue is recorded.
Impact: Can cause lumpy quarterly revenue and affect gross margin interpretation
Management has concluded there is substantial doubt about the company’s ability to continue as a going concern within one year.
Impact: Signals elevated financing and solvency risk
The company has issued convertible notes and other debt-like instruments that may require liability classification or fair value judgments.
Impact: Can affect reported interest expense, liabilities, and dilution analysis
The November 2024 merger changed the reporting structure and requires retroactive presentation adjustments.
Impact: Limits comparability of pre- and post-merger financial statements
Similar listed companies
Publicly listed companies with a comparable business focus.
AbCellera Biologics Inc.
ABCL · Pharmaceutical Preparations
Absci Corp
ABSI · Services-Commercial Physical & Biological Research
Absci Corp is a biotechnology company built around its Integrated Drug Creation platform, which combines AI-driven design, wet-lab biology, and computational…
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
Apollomics Inc.
APLMW · Pharmaceutical Preparations
Anbio Biotechnology
NNNN · In Vitro & In Vivo Diagnostic Substances
Anbio Biotechnology is a U.S.-based diagnostics company organized through a foreign private issuer structure with principal executive offices in Frankfurt, Germany.
Last updated: 24/09/2026